|
|
|
|
|||||
|
|
|
MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now. On August 6, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $7.
The analyst noted that the company reported solid results during the fiscal second quarter of 2025 and is developing its drug pipeline at a steady rate. Khurshid highlighted the company’s progress in treating idiopathic pulmonary fibrosis, nontuberculous mycobacterial lung disease, and pediatric uses of Afrezza.
The analyst acknowledged that while doubts regarding the upcoming TETON-2 study results for Tyvaso in IPF persist, the company’s current valuation remains attractive. This is mainly due to the royalties from Tyvaso DPI in pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.
MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapeutic products for endocrine and rare lung diseases.
While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| 7 hours | |
| Aug-22 | |
| Aug-17 | |
| Aug-06 | |
| Aug-06 | |
| Aug-06 | |
| Aug-06 | |
| Aug-05 | |
| Aug-04 | |
| Aug-01 | |
| Jul-31 | |
| Jul-30 | |
| Jul-30 | |
| Jul-28 | |
| Jul-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite